November 10, 2021

Tivdak™ (tisotumab vedotin-tftv) is now U.S. FDA approved to treat recurrent or metastatic cervical cancer in patients whose disease has progressed on or after chemotherapy.

  • Manufactured by Genmab and Seagen, it is the first antibody-drug conjugate to be FDA approved for this indication.
  • Recommended dosing is 2mg/kg of the patient’s body weight, up to a maximum of 200mg, given via 30-minute intravenous infusion every three weeks until disease progression or unacceptable toxicity occur.
  • Tivdak has a wholesale acquisition cost (WAC) of $5,885 per 40mg single-dose vial.
November 19, 2021

COVID-19 Booster Shots Authorized for All Adults

Read More
November 18, 2021

New Warning Added to Climara Pro Prescribing Information

Read More
November 15, 2021

Besremi Approved for Rare Cancer

Read More
November 15, 2021

Mvasi Receives New Cancer Indication

Read More